Predicting survival of men with recurrent prostate cancer after radical prostatectomy

Paolo Dell'Oglio, Nazareno Suardi, Stephen A. Boorjian, Nicola Fossati, Giorgio Gandaglia, Zhe Tian, Marco Moschini, Umberto Capitanio, Pierre I. Karakiewicz, Francesco Montorsi, Robert Jeffrey Karnes, Alberto Briganti

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Introduction To develop and externally validate a novel nomogram aimed at predicting cancer-specific mortality (CSM) after biochemical recurrence (BCR) among prostate cancer (PCA) patients treated with radical prostatectomy (RP) with or without adjuvant external beam radiotherapy (aRT) and/or hormonal therapy (aHT). Materials & methods The development cohort included 689 consecutive PCA patients treated with RP between 1987 and 2011 with subsequent BCR, defined as two subsequent prostate-specific antigen values >0.2 ng/ml. Multivariable competing-risks regression analyses tested the predictors of CSM after BCR for the purpose of 5-year CSM nomogram development. Validation (2000 bootstrap resamples) was internally tested. External validation was performed into a population of 6734 PCA patients with BCR after treatment with RP at the Mayo Clinic from 1987 to 2011. The predictive accuracy (PA) was quantified using the receiver operating characteristic-derived area under the curve and the calibration plot method. Results The 5-year CSM-free survival rate was 83.6% (confidence interval [CI]: 79.6-87.2). In multivariable analyses, pathologic stage T3b or more (hazard ratio [HR]: 7.42; p = 0.008), pathologic Gleason score 8-10 (HR: 2.19; p = 0.003), lymph node invasion (HR: 3.57; p = 0.001), time to BCR (HR: 0.99; p = 0.03) and age at BCR (HR: 1.04; p = 0.04), were each significantly associated with the risk of CSM after BCR. The bootstrap-corrected PA was 87.4% (bootstrap 95% CI: 82.0-91.7%). External validation of our nomogram showed a good PA at 83.2%. Conclusions We developed and externally validated the first nomogram predicting 5-year CSM applicable to contemporary patients with BCR after RP with or without adjuvant treatment.

Original languageEnglish (US)
Pages (from-to)27-34
Number of pages8
JournalEuropean Journal of Cancer
Volume54
DOIs
StatePublished - Feb 1 2016

Fingerprint

Prostatectomy
Prostatic Neoplasms
Recurrence
Nomograms
Survival
Mortality
Neoplasms
Confidence Intervals
Neoplasm Grading
Prostate-Specific Antigen
ROC Curve
Calibration
Area Under Curve
Radiotherapy
Therapeutics
Survival Rate
Lymph Nodes
Regression Analysis
Population

Keywords

  • Adjuvant treatments
  • Biochemical recurrence
  • Nomogram
  • Prostate cancer
  • Prostate cancer death

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dell'Oglio, P., Suardi, N., Boorjian, S. A., Fossati, N., Gandaglia, G., Tian, Z., ... Briganti, A. (2016). Predicting survival of men with recurrent prostate cancer after radical prostatectomy. European Journal of Cancer, 54, 27-34. https://doi.org/10.1016/j.ejca.2015.11.004

Predicting survival of men with recurrent prostate cancer after radical prostatectomy. / Dell'Oglio, Paolo; Suardi, Nazareno; Boorjian, Stephen A.; Fossati, Nicola; Gandaglia, Giorgio; Tian, Zhe; Moschini, Marco; Capitanio, Umberto; Karakiewicz, Pierre I.; Montorsi, Francesco; Karnes, Robert Jeffrey; Briganti, Alberto.

In: European Journal of Cancer, Vol. 54, 01.02.2016, p. 27-34.

Research output: Contribution to journalArticle

Dell'Oglio, P, Suardi, N, Boorjian, SA, Fossati, N, Gandaglia, G, Tian, Z, Moschini, M, Capitanio, U, Karakiewicz, PI, Montorsi, F, Karnes, RJ & Briganti, A 2016, 'Predicting survival of men with recurrent prostate cancer after radical prostatectomy', European Journal of Cancer, vol. 54, pp. 27-34. https://doi.org/10.1016/j.ejca.2015.11.004
Dell'Oglio, Paolo ; Suardi, Nazareno ; Boorjian, Stephen A. ; Fossati, Nicola ; Gandaglia, Giorgio ; Tian, Zhe ; Moschini, Marco ; Capitanio, Umberto ; Karakiewicz, Pierre I. ; Montorsi, Francesco ; Karnes, Robert Jeffrey ; Briganti, Alberto. / Predicting survival of men with recurrent prostate cancer after radical prostatectomy. In: European Journal of Cancer. 2016 ; Vol. 54. pp. 27-34.
@article{a643682d355649e1aa35867456d6121a,
title = "Predicting survival of men with recurrent prostate cancer after radical prostatectomy",
abstract = "Introduction To develop and externally validate a novel nomogram aimed at predicting cancer-specific mortality (CSM) after biochemical recurrence (BCR) among prostate cancer (PCA) patients treated with radical prostatectomy (RP) with or without adjuvant external beam radiotherapy (aRT) and/or hormonal therapy (aHT). Materials & methods The development cohort included 689 consecutive PCA patients treated with RP between 1987 and 2011 with subsequent BCR, defined as two subsequent prostate-specific antigen values >0.2 ng/ml. Multivariable competing-risks regression analyses tested the predictors of CSM after BCR for the purpose of 5-year CSM nomogram development. Validation (2000 bootstrap resamples) was internally tested. External validation was performed into a population of 6734 PCA patients with BCR after treatment with RP at the Mayo Clinic from 1987 to 2011. The predictive accuracy (PA) was quantified using the receiver operating characteristic-derived area under the curve and the calibration plot method. Results The 5-year CSM-free survival rate was 83.6{\%} (confidence interval [CI]: 79.6-87.2). In multivariable analyses, pathologic stage T3b or more (hazard ratio [HR]: 7.42; p = 0.008), pathologic Gleason score 8-10 (HR: 2.19; p = 0.003), lymph node invasion (HR: 3.57; p = 0.001), time to BCR (HR: 0.99; p = 0.03) and age at BCR (HR: 1.04; p = 0.04), were each significantly associated with the risk of CSM after BCR. The bootstrap-corrected PA was 87.4{\%} (bootstrap 95{\%} CI: 82.0-91.7{\%}). External validation of our nomogram showed a good PA at 83.2{\%}. Conclusions We developed and externally validated the first nomogram predicting 5-year CSM applicable to contemporary patients with BCR after RP with or without adjuvant treatment.",
keywords = "Adjuvant treatments, Biochemical recurrence, Nomogram, Prostate cancer, Prostate cancer death",
author = "Paolo Dell'Oglio and Nazareno Suardi and Boorjian, {Stephen A.} and Nicola Fossati and Giorgio Gandaglia and Zhe Tian and Marco Moschini and Umberto Capitanio and Karakiewicz, {Pierre I.} and Francesco Montorsi and Karnes, {Robert Jeffrey} and Alberto Briganti",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.ejca.2015.11.004",
language = "English (US)",
volume = "54",
pages = "27--34",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Predicting survival of men with recurrent prostate cancer after radical prostatectomy

AU - Dell'Oglio, Paolo

AU - Suardi, Nazareno

AU - Boorjian, Stephen A.

AU - Fossati, Nicola

AU - Gandaglia, Giorgio

AU - Tian, Zhe

AU - Moschini, Marco

AU - Capitanio, Umberto

AU - Karakiewicz, Pierre I.

AU - Montorsi, Francesco

AU - Karnes, Robert Jeffrey

AU - Briganti, Alberto

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Introduction To develop and externally validate a novel nomogram aimed at predicting cancer-specific mortality (CSM) after biochemical recurrence (BCR) among prostate cancer (PCA) patients treated with radical prostatectomy (RP) with or without adjuvant external beam radiotherapy (aRT) and/or hormonal therapy (aHT). Materials & methods The development cohort included 689 consecutive PCA patients treated with RP between 1987 and 2011 with subsequent BCR, defined as two subsequent prostate-specific antigen values >0.2 ng/ml. Multivariable competing-risks regression analyses tested the predictors of CSM after BCR for the purpose of 5-year CSM nomogram development. Validation (2000 bootstrap resamples) was internally tested. External validation was performed into a population of 6734 PCA patients with BCR after treatment with RP at the Mayo Clinic from 1987 to 2011. The predictive accuracy (PA) was quantified using the receiver operating characteristic-derived area under the curve and the calibration plot method. Results The 5-year CSM-free survival rate was 83.6% (confidence interval [CI]: 79.6-87.2). In multivariable analyses, pathologic stage T3b or more (hazard ratio [HR]: 7.42; p = 0.008), pathologic Gleason score 8-10 (HR: 2.19; p = 0.003), lymph node invasion (HR: 3.57; p = 0.001), time to BCR (HR: 0.99; p = 0.03) and age at BCR (HR: 1.04; p = 0.04), were each significantly associated with the risk of CSM after BCR. The bootstrap-corrected PA was 87.4% (bootstrap 95% CI: 82.0-91.7%). External validation of our nomogram showed a good PA at 83.2%. Conclusions We developed and externally validated the first nomogram predicting 5-year CSM applicable to contemporary patients with BCR after RP with or without adjuvant treatment.

AB - Introduction To develop and externally validate a novel nomogram aimed at predicting cancer-specific mortality (CSM) after biochemical recurrence (BCR) among prostate cancer (PCA) patients treated with radical prostatectomy (RP) with or without adjuvant external beam radiotherapy (aRT) and/or hormonal therapy (aHT). Materials & methods The development cohort included 689 consecutive PCA patients treated with RP between 1987 and 2011 with subsequent BCR, defined as two subsequent prostate-specific antigen values >0.2 ng/ml. Multivariable competing-risks regression analyses tested the predictors of CSM after BCR for the purpose of 5-year CSM nomogram development. Validation (2000 bootstrap resamples) was internally tested. External validation was performed into a population of 6734 PCA patients with BCR after treatment with RP at the Mayo Clinic from 1987 to 2011. The predictive accuracy (PA) was quantified using the receiver operating characteristic-derived area under the curve and the calibration plot method. Results The 5-year CSM-free survival rate was 83.6% (confidence interval [CI]: 79.6-87.2). In multivariable analyses, pathologic stage T3b or more (hazard ratio [HR]: 7.42; p = 0.008), pathologic Gleason score 8-10 (HR: 2.19; p = 0.003), lymph node invasion (HR: 3.57; p = 0.001), time to BCR (HR: 0.99; p = 0.03) and age at BCR (HR: 1.04; p = 0.04), were each significantly associated with the risk of CSM after BCR. The bootstrap-corrected PA was 87.4% (bootstrap 95% CI: 82.0-91.7%). External validation of our nomogram showed a good PA at 83.2%. Conclusions We developed and externally validated the first nomogram predicting 5-year CSM applicable to contemporary patients with BCR after RP with or without adjuvant treatment.

KW - Adjuvant treatments

KW - Biochemical recurrence

KW - Nomogram

KW - Prostate cancer

KW - Prostate cancer death

UR - http://www.scopus.com/inward/record.url?scp=84950298858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84950298858&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2015.11.004

DO - 10.1016/j.ejca.2015.11.004

M3 - Article

VL - 54

SP - 27

EP - 34

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -